CO5611107A2 - Sales de valsartan - Google Patents

Sales de valsartan

Info

Publication number
CO5611107A2
CO5611107A2 CO04086386A CO04086386A CO5611107A2 CO 5611107 A2 CO5611107 A2 CO 5611107A2 CO 04086386 A CO04086386 A CO 04086386A CO 04086386 A CO04086386 A CO 04086386A CO 5611107 A2 CO5611107 A2 CO 5611107A2
Authority
CO
Colombia
Prior art keywords
valsartan
salt
salts
tetrahydrate
polymorphs
Prior art date
Application number
CO04086386A
Other languages
English (en)
Inventor
Marti Erwin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5611107A2 publication Critical patent/CO5611107A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

1.- Una sal de valsartan seleccionada de (i) polimorfos del tetrahidrato, (ii) polimorfos del trihidrato, (iii) el monohidrato, y (iv) la di-(sal de calcio de valsartan) pentahidrato,en cada caso de la sal de calcio de valsartan, y el hidrato del mismo;y se seleccionan de: (i) una forma polimórfica del hexahidrato, (ii) el trihidrato, (iii) el monohidrato, y (iv) el tetrahidrato;en cada caso la sal de magnesio de valsartan, y el hidrato del mismo.2.- Una sal de acuerdo con la reivindicación 1, en una forma cristalina, parcialmente cristalina o amorfa.
CO04086386A 2002-02-04 2004-09-02 Sales de valsartan CO5611107A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04

Publications (1)

Publication Number Publication Date
CO5611107A2 true CO5611107A2 (es) 2006-02-28

Family

ID=27734333

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04086386A CO5611107A2 (es) 2002-02-04 2004-09-02 Sales de valsartan

Country Status (18)

Country Link
US (3) US6869970B2 (es)
EP (1) EP1474402A1 (es)
JP (2) JP4895475B2 (es)
KR (3) KR20110101257A (es)
CN (2) CN100548993C (es)
AU (1) AU2003214054B2 (es)
BR (1) BR0307442A (es)
CA (2) CA2474424C (es)
CO (1) CO5611107A2 (es)
EC (1) ECSP045221A (es)
HK (1) HK1139681A1 (es)
MX (1) MXPA04007525A (es)
NO (1) NO328155B1 (es)
NZ (1) NZ534560A (es)
PL (1) PL370481A1 (es)
RU (1) RU2004126862A (es)
WO (1) WO2003066606A1 (es)
ZA (1) ZA200405698B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
SI1515717T1 (sl) * 2002-06-13 2009-02-28 Novartis Ag Kalcijeve soli statinov, izvedenih iz indola
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
JP4783733B2 (ja) * 2003-05-16 2011-09-28 ノバルティス アーゲー バルサルタンを含む医薬組成物
WO2005046677A2 (en) * 2003-11-14 2005-05-26 Novartis Ag At1-receptor antagonists for treating nephrotic syndrome
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
AR061627A1 (es) 2006-06-27 2008-09-10 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
MX2013001251A (es) 2010-08-03 2013-03-18 Novartis Ag Valsartan altamente cristalino.
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59107440D1 (de) * 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
AP9901660A0 (en) * 1997-02-28 1999-09-30 Burstein Lab Inc Laboratory in a disk.
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
HUP0300701A2 (hu) 2000-04-24 2003-07-28 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartarát, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
PE20020613A1 (es) 2000-07-19 2002-08-07 Novartis Ag Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Also Published As

Publication number Publication date
ECSP045221A (es) 2004-09-28
AU2003214054A1 (en) 2003-09-02
CN1628106A (zh) 2005-06-15
PL370481A1 (en) 2005-05-30
RU2004126862A (ru) 2005-06-27
CN101633646B (zh) 2012-08-29
US6869970B2 (en) 2005-03-22
CA2474424C (en) 2013-03-26
MXPA04007525A (es) 2004-11-10
KR20120054667A (ko) 2012-05-30
AU2003214054B2 (en) 2007-08-16
CN100548993C (zh) 2009-10-14
KR20040081178A (ko) 2004-09-20
WO2003066606A1 (en) 2003-08-14
KR20110101257A (ko) 2011-09-15
US20120022268A1 (en) 2012-01-26
US8058301B2 (en) 2011-11-15
HK1139681A1 (en) 2010-09-24
CA2776902A1 (en) 2003-08-14
BR0307442A (pt) 2005-01-04
CN101633646A (zh) 2010-01-27
JP4895475B2 (ja) 2012-03-14
CA2474424A1 (en) 2003-08-14
US20030171414A1 (en) 2003-09-11
JP2009235086A (ja) 2009-10-15
US8329919B2 (en) 2012-12-11
US20050101652A1 (en) 2005-05-12
JP5303370B2 (ja) 2013-10-02
EP1474402A1 (en) 2004-11-10
ZA200405698B (en) 2006-05-31
JP2005517696A (ja) 2005-06-16
NO20043660L (no) 2004-10-12
NO328155B1 (no) 2009-12-21
NZ534560A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
CO5611107A2 (es) Sales de valsartan
NO20050542L (no) Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin
HK1087405A1 (en) Improved production of the rosuvastatin calcium salt
GB2395946B (en) Method for the production of sodium chloride from seawater
EP1757604A4 (en) PROCESS FOR THE PRODUCTION OF SOLIFENACIN OR ITS SALT
HUP0204203A3 (en) Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
EA201000250A1 (ru) Новые соли базедоксифена
WO2005100352A8 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
EP1676835A4 (en) METHOD FOR PRODUCING TRIARYL SULPHONIUM SALTS
PE20081402A1 (es) Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
ATE355255T1 (de) Auflösungshemmende mittel zur herstellung von gereinigten solen
AR054131A1 (es) Hidratos de sales alcalino-terreas de irbesartan y su preparacion
ATE397603T1 (de) Herstellungsverfahren von kristallinem losartan- kaliumsalz
IT1303734B1 (it) Forma cristallina del diclofenac sale sodico.
JP2005213235A5 (es)
TH86119EX (th) สว่าน
RU2002101454A (ru) Препарат для подавления роста сульфатвосстанавливающих бактерий
TH57652EX (th) ขวด
TH83008EX (th) ขวด
TH81673EX (th) ยาดม
TH81672EX (th) ยาดม
TH66356S (th) รองเท้า
TH79231B (th) ภาชนะบรรจุเครื่องประดับ
TH79230B (th) ภาชนะบรรจุเครื่องประดับ
TH79226B (th) ภาชนะบรรจุเครื่องประดับ

Legal Events

Date Code Title Description
FC Application refused